Table 3.
Long-term follow-up (treatment, mortality and survival rates) of the 730 secondary metastatic patients
| Treatment, n/N (%) | |
| Oligometastatic approach | 21/730 (3) |
| Luminal A-like | 6/21 (29) |
| Luminal HER2-like | 3/21 (14) |
| Luminal B-like | 1/21 (5) |
| HER2-like | 2/21 (9) |
| Triple-negative | 9/21 (43) |
| Number of patients within the oligometastatic approach group in whom CA 15.3 elevation was the trigger for diagnosis of metastases | 6/21 (29) |
| Number of patients within the group in whom CA 15.3 was the trigger for diagnosis of metastases, who received oligometastatic approach | 6/271 (2) |
| Mortality, n/N (%) | |
| Overall mortality | 570/730 (78) |
| Breast cancer-related mortality | 528/570 (93) |
| Other cause of mortality | 28/570 (5) |
| Reason of mortality unknown | 14/570 (2) |
| Mortality in group in whom CA 15.3 was the trigger for the first diagnosis of metastases, n/N (%) | |
| Overall mortality | 196/269 (73) |
| Breast cancer-related mortality | 185/196 (94) |
| Other cause of mortality | 7/196 (4) |
| Reason of mortality unknown | 4/196 (2) |
| Median overall survival in relation to detection method of metastases, in monthsa | |
| Median overall survival in group in whom CA 15.3 was the trigger for the diagnosis of metastases (n = 269) | 35 (29-39) |
| Luminal A-like (n = 128) | 40 (32-46) |
| Luminal HER2-like (n = 23) | 33 (18-42) |
| Luminal B-like (n = 80) | 34 (26-40) |
| HER2-like (n = 17) | 21 (10-60) |
| Triple-negative (n = 21) | 14 (5-26) |
| Median overall survival in groups in whom CA 15.3 was NOT the trigger for the diagnosis of metastases (n = 461) | 22 (18-26) |
| Luminal A-like (n = 137) | 36 (29-46) |
| Luminal HER2-like (n = 29) | 25 (15-37) |
| Luminal B-like (n = 135) | 27 (20-30) |
| HER2-like (n = 39) | 32 (14-44) |
| Triple-negative (n = 121) | 12 (9-16) |
HER2, human epidermal growth factor receptor 2.
a
95% Confidence interval.